


Y03-076USRCE.non-finalresponse 6-10 2
 Serial No. 10/676,287

In the Claims:

Please amend the claims as follows.

1-38. Canceled.

39. (Currently amended) A method of treating the symptomology of menopause in a patient while reducing the risk that the patient develops an estrogen-sensitive cancer, the method comprising administering to said patient an effective amount of a selective estrogen receptor modulator (SERM) which has the chemical structure:



Where R is a sidechain group of at least 5 non-hydrogen atoms in length selected

from a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} YR^1$ group, a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} YCR^2$ group, a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} CR^3$ group, or a $-(CH_2)_n XR^4$ group,

R^1 , R^2 , R^3 and R^4 are each independently a C_1 - C_6 linear, branch-chained or cyclo-alkyl group;

R_1 is H, CH_3 , a vinyl group ($-CH=CH_2$), or an ethynyl group ($-C\equiv CH$);

X is O or S and Y is O; and


Y03-076USRCE.non-finalresponse 6-10 3
Serial No. 10/676,287

n is from 1 to 3, wherein said symptomology is one or more of bone loss associated with osteoporosis, elevated cholesterol, or elevated low-density lipoproteins (LDL) ~~or cardiovascular disease associated with elevated cholesterol or elevated low-density lipoproteins (LDL).~~

40. (Previously presented) The method according to claim 39 wherein said menopausal symptomology is bone loss associated with osteoporosis.
41. (Previously presented) The method according to claim 40 wherein R is an ester or thioester group and R¹ and R² are each independently a C₁-C₅ linear, branch-chained or cyclo- alkyl group.
42. (Currently amended) The method according to claim 39 wherein said compound is orally administered to said patient and said estrogen-sensitive cancer is breast cancer.
43. (Previously presented) The method according to claim 40 wherein said selective estrogen receptor modulator (SERM) is orally administered to said patient.
44. (Previously presented) The method according to claim 41 wherein X is O.
45. (Previously presented) The method according to claim 40 wherein X is O and R₁ is an ethynyl group.
46. (Previously presented) The method according to claim 40 wherein when R is an ester group and n is 1, and R¹ and R² have at least two carbon atoms.

Y03-076USRCE.non-finalresponse 6-10 4
Serial No. 10/676,287

47. (Previously presented) The method according to claim 40 wherein when R is a keto, thioketo, ether or thioether group, n is 1, and R³ and R⁴ have at least three carbon atoms.
48. (Currently amended) A method of treating a patient suffering from an estrogen-sensitive cancer, the method comprising administering to said patient an effective amount of a selective estrogen receptor modulator (SERM) which has the chemical structure:



Where R is a sidechain group of at least 5 non-hydrogen atoms in length selected

from a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} Y R^1$ group, a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} R^2$ group, a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} R^3$ group, or a $-(CH_2)_n X R^4$ group,

R¹, R², R³ and R⁴ are each independently a C₁-C₆ linear, branch-chained or cyclo-alkyl group;

R₁ is H, CH₃, a vinyl group (-CH=CH₂), or an ethynyl group (-C≡CH);

X is O or S and Y is O; and

n is from 1 to 3; and


~~wherein administration of the SERM does not exacerbate symptoms of the cancer and reduces the risk that the patient develops another estrogen sensitive cancer.~~

Y03-076USRCE.non-finalresponse 6-10 5
Serial No. 10/676,287

49. (Previously presented) The method according to claim 48 wherein said estrogen-sensitive cancer is breast cancer.
50. (Previously presented) The method according to claim 49 wherein R is an ester or thioester group and R^1 and R^2 are each independently a C_1 - C_5 linear, branch-chained or cyclo- alkyl group.
51. (Previously presented) The method according to claim 49 wherein said selective estrogen receptor modulator (SERM) is orally administered to said patient.
52. (Previously presented) The method according to claim 40 wherein said selective estrogen receptor modulator (SERM) is orally administered to said patient.
53. (Previously presented) The method according to claim 41 wherein X is O.
54. (Previously presented) The method according to claim 40 wherein X is O and R_1 is an ethynyl group.
55. (Previously presented) The method according to claim 40 wherein when R is an ester group and n is 1, and R^1 and R^2 have at least two carbon atoms.
56. (Previously presented) The method according to claim 40 wherein when R is a keto, thioketo, ether or thioether group, n is 1, and R^3 and R^4 have at least three carbon atoms.

Y03-076USRCE.non-finalresponse 6-10 6
Serial No. 10/676,287

57. (Currently amended) A method of reducing the likelihood of a recurrence of breast cancer in a patient ~~in remission from breast cancer, the method~~ comprising administering to said patient an effective amount of a selective estrogen receptor modulator (SERM) which has the chemical structure:



Where R is a sidechain group of at least 5 non-hydrogen atoms in length selected

from a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} Y R^1$ group, a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} Y R^2$ group, a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} R^3$ group, or a $-(CH_2)_n X R^4$ group,

R^1 , R^2 , R^3 and R^4 are each independently a C_1 - C_6 linear, branch-chained or cyclo-alkyl group;

R_1 is H, CH_3 , a vinyl group ($-CH=CH_2$), or an ethynyl group ($-C\equiv CH$);

X is O or S and Y is O, and


n is from 1 to 3.

58. (Previously presented) The method according to claim 57 wherein wherein R is an ester or thioester group and R^1 and R^2 are each independently a C_1 - C_5 linear, branch-chained or cyclo- alkyl group.

Y03-076USRCE.non-finalresponse 6-10 7
Serial No. 10/676,287

59. (Previously presented) The method according to claim 57 wherein said compound is orally administered to said patient.
60. (Previously presented) The method according to claim 58 wherein said compound is orally administered to said patient.
61. (Previously presented) The method according to claim 57 wherein X is O.
62. (Previously presented) The method according to claim 57 wherein X is O and R₁ is an ethynyl group.
63. (Previously presented) The method according to claim 57 wherein when R is an ester group and n is 1, and R¹ and R² have at least two carbon atoms.
64. (Previously presented) The method according to claim 57 wherein when R is a keto, thioketo, ether or thioether group, n is 1, and R³ and R⁴ have at least three carbon atoms.
65. (Currently amended) A method of treating the symptomology of menopause in a patient suffering from an estrogen-sensitive cancer, the method comprising administering to said patient an effective amount of a selective estrogen receptor modulator (SERM) which has the chemical structure:

Y03-076USRCE.non-finalresponse 6-10 8
Serial No. 10/676,287



Where R is a sidechain group of at least 5 non-hydrogen atoms in length selected

from a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} Y R^1$ group, a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} Y R^2$ group, a $-(CH_2)_n \overset{\overset{X}{\parallel}}{C} R^3$ group, or
a $-(CH_2)_n X R^4$ group,

R^1 , R^2 , R^3 and R^4 are each independently a C_1 - C_6 linear, branch-chained or cyclo-alkyl group;

R_1 is H, CH_3 , a vinyl group ($-CH=CH_2$), or an ethynyl group ($-C\equiv CH$);

X is O or S and Y is O; and

n is from 1 to 3, wherein said symptomology of menopause is one or more of bone loss associated with osteoporosis, elevated cholesterol, or elevated low-density lipoproteins (LDL) ~~or cardiovascular disease associated with elevated cholesterol or elevated low-density lipoproteins (LDL); and~~

~~wherein administration of the SERM does not exacerbate symptoms of the cancer and reduces the risk that the patient develops another estrogen-sensitive cancer.~~

66. (Previously presented) The method according to claim 65 wherein said menopausal symptomology is bone loss associated with osteoporosis.

Y03-076USRCE.non-finalresponse 6-10 9
Serial No. 10/676,287

67. (Previously presented) The method according to claim 65 wherein wherein R is an ester or thioester group and R^1 and R^2 are each independently a C_1 - C_5 linear, branch-chained or cyclo- alkyl group.
68. (Previously presented) The method according to claim 65 wherein said selective estrogen receptor modulator (SERM) is orally administered to said patient.
69. (Previously presented) The method according to claim 66 wherein said selective estrogen receptor modulator (SERM) is orally administered to said patient.
70. (Previously presented) The method according to claim 65 wherein X is O.
71. (Previously presented) The method according to claim 65 wherein X is O and R_1 is an ethynyl group.
72. (Previously presented) The method according to claim 65 wherein when R is an ester group and n is 1, and R^1 and R^2 have at least two carbon atoms.
73. (Previously presented) The method according to claim 65 wherein when R is a keto, thioketo, ether or thioether group, n is 1, and R^3 and R^4 have at least three carbon atoms.
74. (New) The method according to claim 65 wherein said estrogen-sensitive cancer is breast cancer.

Y03-076USRCE-non-finalresponse 6-10 10
Serial No. 10/676,287

75. (New) The method according to claim 66 wherein said estrogen-sensitive cancer is breast cancer.